Vivek Ramaswamy - 02 Apr 2024 Form 3 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
10%+ Owner
Signature
By: /s/ Stephen Roberts, as Attorney-in-Fact for Vivek Ramaswamy
Issuer symbol
ROIV
Transactions as of
02 Apr 2024
Net transactions value
$0
Form type
3
Filing time
12 Apr 2024, 18:01:26 UTC
Previous filing
03 Jan 2024
Next filing
27 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ROIV Common Shares 53,431,426 02 Apr 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ROIV Stock Option (Right to Buy) 02 Apr 2024 Common Shares 21,856,138 $12.68 Direct F1
holding ROIV Stock Option (Right to Buy) 02 Apr 2024 Common Shares 1,753,905 $13.78 Direct F1
holding ROIV Stock Option (Right to Buy) 02 Apr 2024 Common Shares 5,915,052 $15.85 Direct F1
holding ROIV Capped Value Appreciation Rights 02 Apr 2024 Common Shares 11,570,769 $11.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects an award of stock options to purchase Common Shares that is fully vested.
F2 Reflects a fully service-vested award of capped value appreciation rights ("CVARs") that, upon achievement of the hurdle price condition based on the hurdle price reflected in column 4 of Table II above on an applicable measurement date, entitle the reporting person to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price reflected in column 4 of Table II above (such excess, the "CVAR Amount"). The CVARs will be settled in a number of Common Shares determined by dividing (i) the applicable CVAR Amount by (ii) the fair market value of a Common Share as of the applicable payment date.

Remarks:

The reporting person became a 10% shareholder of the Issuer following the repurchase of Common Shares announced by the Issuer on April 2, 2024 and not through any transaction by the reporting person.